Medicines Co. (MDCO) news stock charts
Medicines Co. (MDCO) Investment Summary:
The Medicines Company, a pharmaceutical company, provides acute care hospital products worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients undergoing percutaneous coronary interventions or coronary angioplasty. The company’s late-stage development products include Cleviprex, a drug that is intended for the reduction and control of blood pressure in intensive care patients; and cangrelor, an intravenous antiplatelet agent that prevents platelet activation and aggregation. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The company sells its produc...www.themedicinescompany.com
Founded in 1996
MEDICINES COMPANY (MDCO:NASDAQ)
LAST $7.88 USD
CHANGE TODAY -1.42 -15.27%
VOLUME 6.4M
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of MEDICINES COMPANY (MDCO)
|
OPEN
$9.35
|
PREVIOUS CLOSE
$9.30
|
|
|
DAY HIGH
$9.92
|
DAY LOW
$7.75
|
|
|
52 WEEK HIGH
09/11/09 - $12.12
|
52 WEEK LOW
05/13/09 - $6.15
|
|
|
MARKET CAP
417.7M
|
AVERAGE VOLUME 10 D
1.2M
|
|
|
EPS TTM
$-0.35
|
SHARES OUTSTANDING
53.0M
|
|
|
MDCO Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for MEDICINES COMPANY (MDCO)
Medicines Co. Expands Nationwide Recall for Certain Lots of Cleviprex
03/17/2010
Medicines Co. announced that it is voluntarily expanding the recall of Cleviprex (r) (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled. The four additional Cleviprex lots are 68-407-DJ, Exp. 08/2010; 68-408-DJ, Exp. 08/2011; 71-101-DJ and 71-106-DJ, Exp. 11/2011. The previously recalled lots were 61-978-DW, 61-979-DW, and 61-980-DW, Exp. 01/2010; 68-404-DJ, 68-405-DJ, and 68-406-DJ, Exp. 08/2010; 69-830-DJ, 63-385-DJ, 63-386-DJ, and 63-266-DJ, Exp 03/2011; and 64-453-DJ, Exp. 04/2011. The company is cooperating with the U.S. Food and Drug Administration on this recall.
Medicines Co. expected to Report Q1 2010 Results on April 26, 2010. This event was calculated by Capital IQ (Created on February 17, 2010).
02/17/2010
Medicines Co. expected to Report Q1 2010 Results on April 26, 2010. This event was calculated by Capital IQ (Created on February 17, 2010).
Medicines Co. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009
02/17/2010
Medicines Co. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported net loss of $73.5 million, or $1.40 per diluted share, compared to a net loss of $4.2 million, or $0.08 per diluted share, for the fourth quarter of 2008. This loss was driven mainly by four items totaling $79.0 million. Non-GAAP net loss was $25.6 million or $0.49 per diluted share, compared to non-GAAP net income of $1.8 million, or $0.03 per diluted share for the fourth quarter of 2008, the companys net revenue increased by 8.7% to $102.1 million from $93.9 million in the fourth quarter of 2008. Loss from operations was $25 million and loss before income taxes of $30 million compared to loss from operations of $2.5 million and loss before income taxes of $2.5 million for the same quarter a year ago. For the full year, the company's net revenue increased by $56 million or 16.1% to $404.2 million from $348.2 million in 2008. Net loss was $76.2 million, or $1.46 per diluted share, compared to a net loss of $8.5 million, or $0.16 per diluted share, for 2008. This loss was driven mainly by four items totaling $90.5 million. Non-GAAP net loss was $4.8 million or $0.09 per diluted share compared to non-GAAP net income of $37.2 million, or $0.72 per diluted share for 2008. Loss from operations was $25.3 million and loss before income taxes of $28.2 million compared to loss from operations of $10.8 million and loss before income taxes of $5.6 million for the previous year.
Medicines Co. financial resources
MDCO Competitors
| Company | Last | Change |
| Celera Corp | $6.92 USD | +0.04 |
| Eli Lilly & Co | $36.17 USD | -0.19 |
| Gen-Probe Inc | $47.44 USD | +0.49 |
| Medicure Inc | $0.01 USD | +0.0005 |
| Merck & Co Inc | $38.06 USD | -0.39 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | MDCO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.2x |
|
| Price/Book | 2.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.8x |
|
|
MDCO |
||
|
MDCO transactions
| Type Date |
Target |
|
Merger/Acquisition
December 18, 2009 |
Pfizer Inc., ApoA-I Milano |
|
Private Placement
September 29, 2009 |
Eagle Pharmaceuticals, Inc. |
More Recent Financial News About Medicines Co.
The Medicines Company Expands a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter
2010-03-19 03:22:09
Quote: Press ReleaseSource: The Medicines CompanyOn Wednesday March 17, 2010, 9:00 am EDTThe Medicines Company (: - ) announced today that it is voluntarily expanding the recall of Cleviprex ® (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled. The four additional Cleviprex lots are 68-407-DJ, Exp. 08/2010; 68-408-DJ, Exp. 08/2011; 71-101-DJ and 71-106-D...Read article
Liberty Analytics Co. Initiates Independent Research Coverage on The Medicines Company
2010-03-19 03:22:08
Quote: Press ReleaseSource: Liberty Analytics CompanyOn Thursday March 18, 2010, 9:15 am EDTCALGARY, Alberta, March 18, 2010 (GLOBE NEWSWIRE) -- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on The Medicines Company (: - ). Liberty Analytics is currently offering a complimentary trial subscription. To view our research, go to:Liberty Analytics Co. is a leading provider of independent investment research in North Americ...Read article
The Medicines Company Expands a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter
2010-03-18 04:28:26
Quote: Press ReleaseSource: The Medicines CompanyOn Wednesday March 17, 2010, 9:00 am EDTThe Medicines Company (: - ) announced today that it is voluntarily expanding the recall of Cleviprex ® (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials. Four (4) additional lots of Cleviprex are being recalled. The four additional Cleviprex lots are 68-407-DJ, Exp. 08/2010; 68-408-DJ, Exp. 08/2011; 71-101-DJ and 71-106-D...Read article
MEDICINES CO /DE Files SEC form 8-K, Other Events
2010-03-18 04:28:26
Quote: Other Events
On March 16, 2010, The Medicines Company (the "Company") announced that the U.S.
District Court for the Eastern District of Virginia issued an order in the
Company's lawsuit against the U.S. Patent and Trademark Office, the U.S. Food
and Drug Administration, the U.S. Department of Health and Human Services, et
al. The full text of the press release issued in connection with the
announcement is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
...Read article
The Medicines Company Announces Decision in PTO and FDA Litigation
2010-03-18 04:28:26
Quote: The Court further ordered that the PTO take the actions necessary to ensure that '404 patent does not expire pending resolution of the court proceedings.About The Medicines CompanyNASDAQMDCONewswww.themedicinescompany.com.Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities...Read article
Biotech Stocks: Abraxis, Medicines Co. in spotlight
2010-03-18 04:28:25
Keywords: Markets|U.S. & Canada, ABII, Abraxis Bioscience Inc New, MDCO, Medicines Co (The), MIPI, Molecular Insight Pharmaceuticals Inc, DRG, Nyse Arca Pharmaceutical, BTK, Nyse Arca Biotechnology Inde
Quote: Abraxane is already on the market to treat breast cancer.Meanwhile, The Medicines Co./quotes/comstock/15*!mdco/quotes/nls/mdco(MDCO9.83,+1.57,+19.01%) saw its shares shoot up 20% to $9.93.The drug developer said that it won a legal round in its ongoing litigation against the Patent and Trademark Office, the Food and Drug Administration, and Department of Health and Human Services. The company has been fighting for an extension on a key patent on Angiomax, one of its leading products.On the downs...Read article
The Medicines Company Announces Decision in PTO and FDA Litigation
2010-03-17 02:52:57
Quote: The Court further ordered that the PTO take the actions necessary to ensure that '404 patent does not expire pending resolution of the court proceedings.About The Medicines CompanyNASDAQMDCONewswww.themedicinescompany.com.Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities...Read article
The Medicines Company Earnings Call scheduled for 8:30 am ET today
2010-03-04 04:46:30
Quote: Call DetailsThe Medicines Company Earnings Conference Call (Q4 2009)Wed,
Feb 17, 2010, 8:30 am EasternAbout The Medicines CompanyMDCO)The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine ...Read article
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
2010-03-02 04:43:48
Quote: The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).About The Medicines CompanyMDCONewswww.themedicinescompany.com.Statements contained in this press release about The Medicines Company that are not purely historical, an...Read article
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
2010-03-01 01:26:55
Quote: The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).About The Medicines CompanyMDCONewswww.themedicinescompany.com.Statements contained in this press release about The Medicines Company that are not purely historical, an...Read article
Medicines Co. 4Q loss widens on charges
2010-03-01 01:26:55
Quote: (AP) -- Drugmaker The Medicines Co. on Wednesday said its loss widened in the fourth quarter due to a series of one-time costs, including a tax reserve charge and acquisition expenses.The company said it lost $73.5 million, or $1.40 per share, during the quarter. That compares with a loss of $4.2 million, or 8 cents per share, in the same period of 2008.During the latest quarter, Medicines Co. paid $48.1 million to set up a reserve against its deferred tax assets; a $17.5 million payment to buy ...Read article
For U.S. Audiences Only: The Medicines Company Reports Full Year and Fourth Quarter 2009 Financial Results
2010-03-01 01:26:55
Quote: A
reconciliation of GAAP results with non-GAAP results may also be found in
the attached financial tables.www.themedicinescompany.com.The dial in information is listed below:�
Domestic Dial In800.599.9829
International Dial In:617.847.8703
Passcode for both dial in numbers:95981334
Replay is available from 11:30 a.m. Eastern Time following the conference
call through February 24, 2010.To hear a replay of the call, dial
888-286-8010 (domestic) and 617-801-6888 (international).Passcode for
bo...Read article
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
2010-03-01 01:26:54
Quote: The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).About The Medicines CompanyMDCONewswww.themedicinescompany.com.Statements contained in this press release about The Medicines Company that are not purely historical, an...Read article
Medicines Co. 4Q loss widens on charges
2010-02-25 02:56:24
Quote: (AP) -- Drugmaker The Medicines Co. on Wednesday said its loss widened in the fourth quarter due to a series of one-time costs, including a tax reserve charge and acquisition expenses.The company said it lost $73.5 million, or $1.40 per share, during the quarter. That compares with a loss of $4.2 million, or 8 cents per share, in the same period of 2008.During the latest quarter, Medicines Co. paid $48.1 million to set up a reserve against its deferred tax assets; a $17.5 million payment to buy ...Read article
MEDICINES CO /DE Files SEC form 8-K, Results of Operations and Financial Condition
2010-02-24 01:00:51
Quote: Results of Operations and Financial Condition.
On February 17, 2010, The Medicines Company (the "Company") issued a press
release (the "Earnings Press Release") announcing its results of operations for
the quarter and year ended December 31, 2009. On the same date, the Company held
a conference call, which was open to the public, to discuss these results. A
copy of the Earnings Press Release, a transcript of the related conference call
and conference call summary (which is ...Read article
Medicines Co. 4Q loss widens on charges
2010-02-23 01:35:18
Quote: (AP) -- Drugmaker The Medicines Co. on Wednesday said its loss widened in the fourth quarter due to a series of one-time costs, including a tax reserve charge and acquisition expenses.The company said it lost $73.5 million, or $1.40 per share, during the quarter. That compares with a loss of $4.2 million, or 8 cents per share, in the same period of 2008.During the latest quarter, Medicines Co. paid $48.1 million to set up a reserve against its deferred tax assets; a $17.5 million payment to buy ...Read article
For U.S. Audiences Only: The Medicines Company Reports Full Year and Fourth Quarter 2009 Financial Results
2010-02-19 03:56:00
Quote: A
reconciliation of GAAP results with non-GAAP results may also be found in
the attached financial tables.www.themedicinescompany.com.The dial in information is listed below:�
Domestic Dial In800.599.9829
International Dial In:617.847.8703
Passcode for both dial in numbers:95981334
Replay is available from 11:30 a.m. Eastern Time following the conference
call through February 24, 2010.To hear a replay of the call, dial
888-286-8010 (domestic) and 617-801-6888 (international).Passcode for
bo...Read article
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
2010-02-19 03:55:59
Quote: The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).About The Medicines CompanyMDCONewswww.themedicinescompany.com.Statements contained in this press release about The Medicines Company that are not purely historical, an...Read article
Medicines Co. 4Q loss widens on charges
2010-02-19 03:55:59
Quote: (AP) -- Drugmaker The Medicines Co. on Wednesday said its loss widened in the fourth quarter due to a series of one-time costs, including a tax reserve charge and acquisition expenses.The company said it lost $73.5 million, or $1.40 per share, during the quarter. That compares with a loss of $4.2 million, or 8 cents per share, in the same period of 2008.During the latest quarter, Medicines Co. paid $48.1 million to set up a reserve against its deferred tax assets; a $17.5 million payment to buy ...Read article
MEDICINES CO /DE Files SEC form 8-K, Results of Operations and Financial Condition
2010-02-19 03:55:59
Quote: Item 2.02.Results of Operations and Financial Condition.
On February 17, 2010, The Medicines Company (the "Company") announced
financial results for the quarter and year ended December 31, 2009. The full
text of the press release issued in connection with the announcement is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange ...Read article
Would you like to leave a comment about Medicines Co. MDCO
Find out what social network information about Medicines Co. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Medicines Co.'s Stock there is more great penny stock and market information at Realpennies